Genetic Testing in Medullary Thyroid Carcinoma Syndromes: Mutation Types and Clinical Significance
- 31 May 1997
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 72 (5) , 430-436
- https://doi.org/10.4065/72.5.430
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Genetic basis of endocrine disease: multiple endocrine neoplasia type 2Journal of Clinical Endocrinology & Metabolism, 1995
- Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2BScience, 1995
- Genetic Testing in the Diagnosis and Management of Multiple Endocrine Neoplasia Type IIAnnals of Internal Medicine, 1995
- RET proto-oncogene mutations in French MEN 2A and FMTC familiesHuman Molecular Genetics, 1994
- Predictive DNA Testing and Prophylactic Thyroidectomy in Patients at Risk for Multiple Endocrine Neoplasia Type 2AAnnals of Surgery, 1994
- Advances in Genetic Screening for Multiple Endocrine Neoplasia Type 2 and the Implications for Management of Children at RiskThe Endocrinologist, 1994
- Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.Proceedings of the National Academy of Sciences, 1994
- Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTCNature Genetics, 1994
- A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaNature, 1994
- Genetic Screening for Multiple Endocrine Neoplasia Type 2Experimental and Clinical Endocrinology & Diabetes, 1993